Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA adcom recommends withdrawal of Covis Pharma’s preterm birth drug Makena

By Brian Buntz | October 19, 2022

Covis PharmaFDA’s independent Obstetrics, Reproductive, and Urologic Drugs Advisory Committee has voted almost unanimously that FDA should withdraw its approval of Makena (hydroxyprogesterone caproate injection). A total of 14 of the 15 committee members supported the withdrawal of the drug. In addition, all of the committee concluded that the postmarket study for Makena did not show a benefit.

Makena is the only FDA-approved therapy with an indication of reducing the risk of preterm birth in pregnant women who have had an earlier spontaneous preterm birth.

The drug has a complicated regulatory history. In 2006, Adeza filed a new drug application for the drug, which was then known as Gestiva. Adeza filed a new drug application for the drug, which was then known as Gestiva. The drug would ultimately end up in the hands of Covis and be rebranded as Makena.

The launch of Makena was delayed until 2011.

A postmarket study would eventually conclude that the drug was ineffective.

FDA advisors’ recommendation to pull the drug from the U.S. market was another blow to the agency’s accelerated approval program. The FDA’s decision to assign Biogen’s Alzheimer’s drug Aduhlem (aducanumab) to the program and ultimately approve the drug in 2021 was another source of controversy. The uptake of aducanumab has fallen far below analysts’ expectations, and Medicare decided to constrain reimbursement of the drug to clinical trial recipients.

However, Raghav Chari, chief innovation officer at Covis, says the company believes that “Makena is effective in a higher-risk patient population,” Chari said in a news release. “We will work collaboratively with the FDA to clarify the next steps in this process.”

Covis estimates that 350,000 women in the U.S. have received the drug in the past decade.

Roughly one in 10 babies born in the U.S. is born preterm, according to The March of Dimes. The rate is higher for diverse populations — affecting 14.2% of Black infants and 11.6% of American Indian/Alaska natives.

Covis Pharma is a private company.

In 2016, Australian researchers discovered that a drug that blocks inflammation pathways prevented early birth in pregnant mice.


Filed Under: Obstetrics & gynecology
Tagged With: Covis, Covis Pharma, Makena
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Endometriosis: An immune disease
Biomimetic digital twin ecosystem process tailored for the analysis.
Study combines biomimetic AI, digital twins and multiomics to unveil potential genetic drivers of endometriosis
positive pregnancy test in the hands of a girl close-up
The rise of ‘Ozempic babies’ and the uncharted territory of semaglutide in pregnancy
Mid-section portrait of unrecognizable woman during last months of pregnancy holding her big belly gently standing against wall in blue room
A J&J veteran highlights listening to address overlooked maternal-fetal needs
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE